Results 131 to 140 of about 1,615,665 (249)

Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent

open access: yes, 2009
Brian Casserly, James R KlingerDivision of Pulmonary and Critical Care Medicine, The Memorial Hospital of Rhode Island, Pawtucket, RI, Rhode Island Hospital, Providence, RI, Alpert Medical School of Brown University, Providence, RI, USAAbstract:
James R Klinger, Brian Casserly
core  

Diagnostic tools in pulmonary arterial hypertension management

open access: yes, 2010
An accurate differential diagnosis is crucial in pulmonary hypertension/pulmonary arterial hypertension (PH/PAH), because the treatment options in the different PH/PAH groups and subgroups differ substantially.
Heinrike Wilkens   +5 more
core   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti   +52 more
wiley   +1 more source

2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension

open access: yes, 2017
Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a.,mean pulmonary arterial pressure exceeding 25 mmHg at rest.
Hsu, Chih-Hsin;Ho, Wan-Ling;Huang, Wei-Chun;Chiu, Yu-Wei;Hsu, Tsu-Shiu;Kuo, Ping-Hung;Hsu, Hsao-Hsun;Chang, Jia-Kan;Cheng, Chin-Chang;Lai, Chao-Lun;Liang, Kae-Woei;Lin, Shoa-Lin;Sung, Shih-Hsien;Tsai, Wei-Chuan;Weng, Ken-Pen;Hsieh, Kai-Sheng;Yin, Wei-Hsian;Lin, Shing-Jong;Wang, Kuo-Yang   +1 more
core  

Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analyzed treatment‐naive patients with SSc‐PAH from the European
Hilde Jenssen Bjørkekjær   +63 more
wiley   +1 more source

Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

open access: yes
Summary Background: Pulmonary arterial hypertension (PAH) is a vascular disease characterised by restricted flow and high pressure through the pulmonary arteries, leading to progressive right heart failure and death. This study reports the global burden
GBD 2021 Pulmonary Arterial Hypertension Collaborators
core   +1 more source

Semaphorin 4A Neutralization Reduces Fibrosis and Inflammation in a Mouse Model of Systemic Sclerosis and a 3D Model of Immunity‐Driven Fibrosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective We previously showed that Semaphorin 4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by enzyme‐linked immunosorbent assay in healthy controls (n =
Jaime Marty   +21 more
wiley   +1 more source

Skeletal Muscle Pathology in Pulmonary Arterial Hypertension and Its Contribution to Exercise Intolerance

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Pulmonary arterial hypertension is a disease of the pulmonary vasculature, resulting in elevated pressure in the pulmonary arteries and disrupting the physiological coordination between the right heart and the pulmonary circulation.
Thaís C. F. Menezes   +8 more
doaj   +1 more source

The limits of oral therapy in pulmonary arterial hypertension management

open access: yes, 2015
Qian-Qian Liu,1,2 Zhi-Cheng Jing1,3 1Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2Department of Echocardiography, Fu Wai Hospital, National ...
Liu QQ, Jing ZC
core  

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy